文献速递其他结缔组织病血管炎

安立生坦联合他达拉非初始联合治疗CTD-PAH:AMBITION研究事后分析

Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.
PubMed 文献 · Ann Rheum Dis · 2020-03-11

该事后分析纳入AMBITION研究中216例结缔组织病相关肺动脉高压(CTD-PAH)患者,比较安立生坦联合他达拉非(COMB)与单药治疗(MONO)的临床失败时间。结果显示COMB较MONO降低临床失败风险(CTD-PAH风险降低51.7%,SSc-PAH降低53.7%),在基线低危、中危及第16周低危组中均观察到此获益。

要点

  • COMB较MONO降低CTD-PAH患者临床失败风险51.7%,SSc-PAH亚组降低53.7%。
  • 基线低危组COMB无事件,中危组HR 0.519(95%CI 0.297-0.905)。
  • 第16周低危组HR 0.069(95%CI 0.009-0.548),支持COMB用于低危和中危患者。

核心结论

  • 在CTD-PAH患者中,安立生坦联合他达拉非初始联合治疗较单药治疗降低临床失败风险,尤其在基线具有典型PAH血流动力学特征的患者中。
  • COMB适用于基线低危和中危、随访时低危的CTD-PAH患者。

研究设计与样本

  • AMBITION研究(NCT01178073)的事后分析,纳入改良意向治疗人群中216例CTD-PAH患者(COMB组117例,MONO组99例)。
  • 采用Kaplan-Meier曲线和Cox比例风险回归模型比较组间临床失败时间。

主要发现

  • COMB较MONO的临床失败风险降低:CTD-PAH为51.7%,SSc-PAH为53.7%。
  • 基线低危组COMB无事件(HR未计算),基线中危组HR 0.519(95%CI 0.297-0.905)。
  • 第16周低危组HR 0.069(95%CI 0.009-0.548)。

关键数值与推荐

  • 风险分层采用基线及第16周的低危、中危、高危分组。
  • 临床失败时间(TtCF)为主要评估指标。

临床怎么用

  • 对CTD-PAH患者可考虑安立生坦联合他达拉非初始联合治疗,尤其基线为低危或中危者。
  • 治疗第16周评估为低危的患者可从联合治疗中显著获益。

局限性

  • 为事后分析,非预设亚组分析。
  • 样本量有限(216例),部分亚组事件数少(如基线低危组COMB无事件)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate initial combination therapy with ambrisentan plus tadalafil (COMB) compared with monotherapy of either agent (MONO), and the utility of baseline characteristics and risk stratification in predicting outcomes, in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) and the systemic sclerosis (SSc)-pulmonary arterial hypertension (PAH) subpopulation. METHODS: This post hoc analysis of the Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension (AMBITION) study included patients with CTD-PAH from the modified intention-to-treat population. Time to clinical failure (TtCF) was assessed by baseline characteristics, treatment assignment and risk group (low, intermediate and high) at baseline and week 16. TtCF was compared between groups using Kaplan-Meier curves and Cox proportional hazards regression modelling. RESULTS: The analysis included 216 patients (COMB, n=117; MONO, n=99). The risk of clinical failure was lower with COMB versus MONO (risk reduction: CTD-PAH 51.7%, SSc-PAH 53.7%), particularly in patients with haemodynamic parameters characteristic of typical PAH without features of left heart disease and/or restrictive lung disease at baseline. The risk of clinical failure was lower with COMB versus MONO in the baseline low-risk group (HR not calculated due to no events in COMB), baseline intermediate-risk group (HR 0.519, 95% CI 0.297 to 0.905) and in the week 16 low-risk group (HR 0.069, 95% CI 0.009 to 0.548). CONCLUSIONS: The benefit of COMB over MONO was demonstrated in patients with CTD-PAH, particularly in those with typical PAH haemodynamic characteristics at baseline. COMB is appropriate for patients categorised as low risk and intermediate risk at baseline and low risk at follow-up. TRIAL REGISTRATION NUMBER: NCT01178073.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kuwana M, Blair C, Takahashi T, et al. Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Ann Rheum Dis. 2020. PMID: 32161055. doi:10.1136/annrheumdis-2019-216274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。